Join the Schizophrenia group to help and get support from people like you.
Schizophrenia News (Page 4)
Related terms: Catatonic Schizophrenia, Disorganized Schizophrenia, Paranoid Schizophrenia, Residual Schizophrenia, Schizophrenia, catatonic, Schizophrenia, disorganized, Schizophrenia, paranoid, Schizophrenia, residual, Schizophrenia, undifferentiated, Undifferentiated Schizophrenia
Rates of Sexual Dysfunction High in Patients With Schizophrenia
FRIDAY, Sept. 15, 2023 – There is a high prevalence of sexual dysfunction among individuals with schizophrenia, according to a review published online Sept. 13 in JAMA Psychiatry. Théo Korchia, ...
Tobacco, Cannabis Use Tied to High Rates of Self-Reported Mental Health Issues
FRIDAY, Sept. 15, 2023 – Use of tobacco and/or cannabis, particularly co-use of both substances, is associated with poor mental health, according to a study published online Sept. 13 in PLOS ONE....
ADHD Is Independent Risk Factor for Psychiatric Disorders
THURSDAY, Sept. 7, 2023 – Attention-deficit hyperactivity disorder (ADHD) is an independent risk factor for certain psychiatric disorders, including anorexia nervosa and major depressive disorder,...
Smoking Increases Risk for Mental Illness
TUESDAY, Sept. 5, 2023 – Smoking increases the risk for developing mental disorders, according to a study published online Aug. 21 in Acta Psychiatrica Scandinavica. Lloyd Balbuena, from University...
Higher Risk for Schizophrenia Seen Among Patients With Eczema
TUESDAY, Aug. 8, 2023 – Having atopic dermatitis is associated with a higher risk for schizophrenia and schizoaffective disorder, according to a study published online July 26 in the Archives of...
FDA Approves Uzedy (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
PARSIPPANY, N.J., TEL AVIV & PARIS, April 28, 2023 – Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced t...
FDA Approves Abilify Asimtufii (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults
April 28, 2023 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA)...
FDA Approves Rykindo (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Bipolar 1 Disorder
PRINCETON, N.J., Jan. 15, 2023 /PRNewswire/ -- Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications, today ...
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for Caplyta (lumateperone) for Specific Patient Populations
Caplyta label now includes dosage recommendations for specific patient populations; those with moderate or severe hepatic impairment and patients who are concomitantly taking moderate or strong...
FDA Approves Igalmi (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults
NEW HAVEN, Conn., April 06, 2022 (GLOBE NEWSWIRE) – BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence (AI) approaches to identify and develop...
Intra-Cellular Therapies Announces U.S. FDA Approval of Caplyta (lumateperone) for the Treatment of Bipolar Depression in Adults
Caplyta is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or...
FDA Approves Invega Hafyera (paliperidone palmitate) for Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic ...
FDA Approves Lybalvi (olanzapine and samidorphan) for the Treatment of Schizophrenia and Bipolar I Disorder
DUBLIN, June 1, 2021 /PRNewswire/ – Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved Lybalvi (olanzapine and samidorphan) for the treatment...
FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults
NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) – Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS)...
FDA Approves Secuado (asenapine) Transdermal System for the Treatment of Adults with Schizophrenia
Miami, FL And Jersey City, NJ, October 15, 2019 -- Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced the U.S. Food and Drug Administration ...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Related drug support groups
Seroquel, Abilify, Latuda, quetiapine, Vraylar, olanzapine, risperidone, Zyprexa, aripiprazole, view more... Risperdal, Rexulti, Seroquel XR, Geodon, Invega, Invega Sustenna